FDA Approves Balversa erdafitinib for the Treatment of Metastatic Bladder Cancer

FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer

18:04 EDT 12 Apr 2019 | Drugs.com

April 12, 2019 -- The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration...

More From BioPortfolio on "FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer"